Department of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, United States; Immunology Graduate Program, Stanford University School of Medicine, Stanford, United States; Department of Structural Biology, Stanford University School of Medicine, Stanford, United States
Department of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, United States; Department of Structural Biology, Stanford University School of Medicine, Stanford, United States
Department of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, United States; Department of Structural Biology, Stanford University School of Medicine, Stanford, United States
Department of Biology, University of Osnabrück, Osnabrück, Germany
Fei Mo
Laboratory of Molecular Immunology and Immunology Center, National Heart, Lung, and Blood Institute, NIH, Bethesda, United States
Peng Li
Laboratory of Molecular Immunology and Immunology Center, National Heart, Lung, and Blood Institute, NIH, Bethesda, United States
Magdiel Pérez-Cruz
Division of Blood and Marrow Transplantation, Department of Medicine, Stanford University School of Medicine, Stanford, United States
Peggy P Ho
Department of Neurology and Neurological Sciences, Stanford University, Stanford, United States
Ievgen Koliesnik
Division of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University, Stanford, United States
Nadine Nagy
Division of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University, Stanford, United States
Tereza Hnizdilova
Laboratory of Tumor Immunology, Institute of Microbiology of Czech Academy of Sciences, Prague, Czech Republic
Lora K Picton
Department of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, United States; Department of Structural Biology, Stanford University School of Medicine, Stanford, United States
Division of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University, Stanford, United States
Lawrence Steinman
Department of Neurology and Neurological Sciences, Stanford University, Stanford, United States; Department of Pediatrics, Stanford University, Stanford, United States
Everett Meyer
Division of Blood and Marrow Transplantation, Department of Medicine, Stanford University School of Medicine, Stanford, United States
Department of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, United States; Department of Structural Biology, Stanford University School of Medicine, Stanford, United States; Howard Hughes Medical Institute, Stanford University School of Medicine, Stanford, United States
Interleukin-2 is a pleiotropic cytokine that mediates both pro- and anti-inflammatory functions. Immune cells naturally differ in their sensitivity to IL-2 due to cell type and activation state-dependent expression of receptors and signaling pathway components. To probe differences in IL-2 signaling across cell types, we used structure-based design to create and profile a series of IL-2 variants with the capacity to titrate maximum signal strength in fine increments. One of these partial agonists, IL-2-REH, specifically expanded Foxp3+ regulatory T cells with reduced activity on CD8+ T cells due to cell type-intrinsic differences in IL-2 signaling. IL-2-REH elicited cell type-dependent differences in gene expression and provided mixed therapeutic results: showing benefit in the in vivo mouse dextran sulfate sodium (DSS) model of colitis, but no therapeutic efficacy in a transfer colitis model. Our findings show that cytokine partial agonists can be used to calibrate intrinsic differences in response thresholds across responding cell types to narrow pleiotropic actions, which may be generalizable to other cytokine and growth factor systems.
